Phase I study of oral CI-994 in combination with gemcitabine in treatment of patients with advanced cancer.

@article{Nemunaitis2003PhaseIS,
  title={Phase I study of oral CI-994 in combination with gemcitabine in treatment of patients with advanced cancer.},
  author={John Nemunaitis and Douglas Orr and Rob Eager and Casey C. Cunningham and Adrienne J. Williams and Robert G. Mennel and William Grove and Stephen Olson},
  journal={Cancer journal},
  year={2003},
  volume={9 1},
  pages={58-66}
}
PURPOSE The purpose of this study was to determine the maximum tolerated dose, pharmacokinetic profile, and evidence of antitumor activity of CI-994 used in combination with gemcitabine. METHODS This was a dose escalation trial in which gemcitabine (1,000 mg/m2) was given as a 30-minute infusion on days 1, 8, and 15 of a 28-day cycle. CI-994 was taken orally on consecutive days 1-21 at escalating doses of 2, 4, 6, and 8 mg/m2 per cohort (three patients/cohort). Plasma samples were collected… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

Similar Papers

Loading similar papers…